JP2005526028A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005526028A5 JP2005526028A5 JP2003566002A JP2003566002A JP2005526028A5 JP 2005526028 A5 JP2005526028 A5 JP 2005526028A5 JP 2003566002 A JP2003566002 A JP 2003566002A JP 2003566002 A JP2003566002 A JP 2003566002A JP 2005526028 A5 JP2005526028 A5 JP 2005526028A5
- Authority
- JP
- Japan
- Prior art keywords
- aliphatic
- ring
- benzimidazol
- optionally substituted
- halo
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000001931 aliphatic group Chemical group 0.000 claims description 128
- 229910052739 hydrogen Inorganic materials 0.000 claims description 33
- 229910052736 halogen Inorganic materials 0.000 claims description 19
- 150000002367 halogens Chemical class 0.000 claims description 19
- 239000001257 hydrogen Substances 0.000 claims description 19
- 125000001072 heteroaryl group Chemical group 0.000 claims description 13
- 125000000217 alkyl group Chemical group 0.000 claims description 12
- 125000001424 substituent group Chemical group 0.000 claims description 12
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 7
- 125000003118 aryl group Chemical group 0.000 claims description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 40
- 229910052757 nitrogen Inorganic materials 0.000 claims 27
- 125000005843 halogen group Chemical group 0.000 claims 26
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 17
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 17
- 125000005842 heteroatom Chemical group 0.000 claims 17
- 239000000203 mixture Substances 0.000 claims 17
- 229910052760 oxygen Inorganic materials 0.000 claims 17
- 239000001301 oxygen Chemical group 0.000 claims 17
- 229910052717 sulfur Chemical group 0.000 claims 17
- 239000011593 sulfur Chemical group 0.000 claims 17
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 14
- 150000001875 compounds Chemical class 0.000 claims 13
- 125000000623 heterocyclic group Chemical group 0.000 claims 13
- -1 1,2-methylenedioxy Chemical group 0.000 claims 12
- 125000001118 alkylidene group Chemical group 0.000 claims 12
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 12
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 7
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims 6
- 150000003839 salts Chemical class 0.000 claims 6
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims 5
- 150000002431 hydrogen Chemical class 0.000 claims 5
- CMDJAJYFXCBMBU-UHFFFAOYSA-N 2-[2-(4-amino-1,2,5-oxadiazol-3-yl)benzimidazol-1-yl]-n-(2-fluorophenyl)acetamide Chemical compound NC1=NON=C1C1=NC2=CC=CC=C2N1CC(=O)NC1=CC=CC=C1F CMDJAJYFXCBMBU-UHFFFAOYSA-N 0.000 claims 4
- 125000003341 7 membered heterocyclic group Chemical group 0.000 claims 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims 4
- 206010012601 diabetes mellitus Diseases 0.000 claims 4
- 229920006395 saturated elastomer Polymers 0.000 claims 4
- 208000024891 symptom Diseases 0.000 claims 3
- GLQIZLCZHSQBLY-UHFFFAOYSA-N 2-(1h-benzimidazol-2-yl)-4-chloroaniline Chemical compound NC1=CC=C(Cl)C=C1C1=NC2=CC=CC=C2N1 GLQIZLCZHSQBLY-UHFFFAOYSA-N 0.000 claims 2
- OIIBRYKPFULYFU-UHFFFAOYSA-N 2-[2-(4-amino-1,2,5-oxadiazol-3-yl)benzimidazol-1-yl]-n-(2,6-dimethylphenyl)acetamide Chemical compound CC1=CC=CC(C)=C1NC(=O)CN1C2=CC=CC=C2N=C1C1=NON=C1N OIIBRYKPFULYFU-UHFFFAOYSA-N 0.000 claims 2
- RKDKILJBYDCMPH-UHFFFAOYSA-N 2-[2-(4-amino-1,2,5-oxadiazol-3-yl)benzimidazol-1-yl]-n-(3,4-difluorophenyl)acetamide Chemical compound NC1=NON=C1C1=NC2=CC=CC=C2N1CC(=O)NC1=CC=C(F)C(F)=C1 RKDKILJBYDCMPH-UHFFFAOYSA-N 0.000 claims 2
- CLAATNFGGLOUTN-UHFFFAOYSA-N 2-[2-(4-amino-1,2,5-oxadiazol-3-yl)benzimidazol-1-yl]-n-(3,4-dimethoxyphenyl)acetamide Chemical compound C1=C(OC)C(OC)=CC=C1NC(=O)CN1C2=CC=CC=C2N=C1C1=NON=C1N CLAATNFGGLOUTN-UHFFFAOYSA-N 0.000 claims 2
- IBQVTCXZQBZBDN-UHFFFAOYSA-N 2-[2-(4-amino-1,2,5-oxadiazol-3-yl)benzimidazol-1-yl]-n-(3-fluorophenyl)acetamide Chemical compound NC1=NON=C1C1=NC2=CC=CC=C2N1CC(=O)NC1=CC=CC(F)=C1 IBQVTCXZQBZBDN-UHFFFAOYSA-N 0.000 claims 2
- MZAJMJXYFARZRU-UHFFFAOYSA-N 2-[2-(4-amino-1,2,5-oxadiazol-3-yl)benzimidazol-1-yl]-n-[2-(trifluoromethyl)phenyl]acetamide Chemical compound NC1=NON=C1C1=NC2=CC=CC=C2N1CC(=O)NC1=CC=CC=C1C(F)(F)F MZAJMJXYFARZRU-UHFFFAOYSA-N 0.000 claims 2
- DLHZNLYFGBAMAP-UHFFFAOYSA-N 2-[2-(4-amino-1,2,5-oxadiazol-3-yl)benzimidazol-1-yl]-n-tert-butylacetamide Chemical compound N=1C2=CC=CC=C2N(CC(=O)NC(C)(C)C)C=1C1=NON=C1N DLHZNLYFGBAMAP-UHFFFAOYSA-N 0.000 claims 2
- WVJHNSPIODGZJK-UHFFFAOYSA-N 2-[2-(4-amino-1,2,5-oxadiazol-3-yl)benzimidazol-1-yl]acetamide Chemical compound N=1C2=CC=CC=C2N(CC(=O)N)C=1C1=NON=C1N WVJHNSPIODGZJK-UHFFFAOYSA-N 0.000 claims 2
- VFLJHDYRDURZEP-UHFFFAOYSA-N 2-[2-(4-amino-1,2,5-oxadiazol-3-yl)benzimidazol-1-yl]acetic acid Chemical compound NC1=NON=C1C1=NC2=CC=CC=C2N1CC(O)=O VFLJHDYRDURZEP-UHFFFAOYSA-N 0.000 claims 2
- RSNMFVBZWSSWKA-UHFFFAOYSA-N 2-[2-(4-amino-1,2,5-oxadiazol-3-yl)benzimidazol-1-yl]acetonitrile Chemical compound NC1=NON=C1C1=NC2=CC=CC=C2N1CC#N RSNMFVBZWSSWKA-UHFFFAOYSA-N 0.000 claims 2
- PZFLXZUSYPMQHT-UHFFFAOYSA-N 2-[[2-(4-amino-1,2,5-oxadiazol-3-yl)benzimidazol-1-yl]methyl]benzonitrile Chemical compound NC1=NON=C1C1=NC2=CC=CC=C2N1CC1=CC=CC=C1C#N PZFLXZUSYPMQHT-UHFFFAOYSA-N 0.000 claims 2
- HCRQPXYLXXLKPT-UHFFFAOYSA-N 4-(1-ethylbenzimidazol-2-yl)-1,2,5-oxadiazol-3-amine Chemical compound N=1C2=CC=CC=C2N(CC)C=1C1=NON=C1N HCRQPXYLXXLKPT-UHFFFAOYSA-N 0.000 claims 2
- ZIHIDNWPEZFEMR-UHFFFAOYSA-N 4-(1-methylbenzimidazol-2-yl)-1,2,5-oxadiazol-3-amine Chemical compound N=1C2=CC=CC=C2N(C)C=1C1=NON=C1N ZIHIDNWPEZFEMR-UHFFFAOYSA-N 0.000 claims 2
- BKGOWPYQEFOGAO-UHFFFAOYSA-N 4-(1-prop-2-ynylbenzimidazol-2-yl)-1,2,5-oxadiazol-3-amine Chemical compound NC1=NON=C1C1=NC2=CC=CC=C2N1CC#C BKGOWPYQEFOGAO-UHFFFAOYSA-N 0.000 claims 2
- OOQLAKYHQPZMKP-UHFFFAOYSA-N 4-(1-propan-2-ylbenzimidazol-2-yl)-1,2,5-oxadiazol-3-amine Chemical compound N=1C2=CC=CC=C2N(C(C)C)C=1C1=NON=C1N OOQLAKYHQPZMKP-UHFFFAOYSA-N 0.000 claims 2
- UZZWGLMVBYGQSK-UHFFFAOYSA-N 4-(1-propylbenzimidazol-2-yl)-1,2,5-oxadiazol-3-amine Chemical compound N=1C2=CC=CC=C2N(CCC)C=1C1=NON=C1N UZZWGLMVBYGQSK-UHFFFAOYSA-N 0.000 claims 2
- PAMMUBFLEAQXAD-UHFFFAOYSA-N 4-(6-methyl-1H-benzimidazol-2-yl)-1,2,5-oxadiazol-3-amine Chemical compound N=1C2=CC(C)=CC=C2NC=1C1=NON=C1N PAMMUBFLEAQXAD-UHFFFAOYSA-N 0.000 claims 2
- KNJOGMJHNSVZCC-UHFFFAOYSA-N 4-[1-(2h-tetrazol-5-ylmethyl)benzimidazol-2-yl]-1,2,5-oxadiazol-3-amine Chemical compound NC1=NON=C1C1=NC2=CC=CC=C2N1CC1=NNN=N1 KNJOGMJHNSVZCC-UHFFFAOYSA-N 0.000 claims 2
- LLDVRUBUBPSOMY-UHFFFAOYSA-N 4-[1-(cyclopropylmethyl)benzimidazol-2-yl]-1,2,5-oxadiazol-3-amine Chemical compound NC1=NON=C1C1=NC2=CC=CC=C2N1CC1CC1 LLDVRUBUBPSOMY-UHFFFAOYSA-N 0.000 claims 2
- ROJIDUVOWRJHNV-UHFFFAOYSA-N 4-[1-[(2,4-dichlorophenyl)methyl]benzimidazol-2-yl]-1,2,5-oxadiazol-3-amine Chemical compound NC1=NON=C1C1=NC2=CC=CC=C2N1CC1=CC=C(Cl)C=C1Cl ROJIDUVOWRJHNV-UHFFFAOYSA-N 0.000 claims 2
- GXKYZANVBKVGOS-UHFFFAOYSA-N 4-[1-[(2,6-dichlorophenyl)methyl]benzimidazol-2-yl]-1,2,5-oxadiazol-3-amine Chemical compound NC1=NON=C1C1=NC2=CC=CC=C2N1CC1=C(Cl)C=CC=C1Cl GXKYZANVBKVGOS-UHFFFAOYSA-N 0.000 claims 2
- CPRADZBJYGDHHF-UHFFFAOYSA-N 4-[1-[(2-chloro-6-fluorophenyl)methyl]benzimidazol-2-yl]-1,2,5-oxadiazol-3-amine Chemical compound NC1=NON=C1C1=NC2=CC=CC=C2N1CC1=C(F)C=CC=C1Cl CPRADZBJYGDHHF-UHFFFAOYSA-N 0.000 claims 2
- HIUITJWNRMJIBF-UHFFFAOYSA-N 4-[1-[(2-methylphenyl)methyl]benzimidazol-2-yl]-1,2,5-oxadiazol-3-amine Chemical compound CC1=CC=CC=C1CN1C2=CC=CC=C2N=C1C1=NON=C1N HIUITJWNRMJIBF-UHFFFAOYSA-N 0.000 claims 2
- VHBPIHGCMKHKLE-UHFFFAOYSA-N 4-[1-[(3,4-dichlorophenyl)methyl]benzimidazol-2-yl]-1,2,5-oxadiazol-3-amine Chemical compound NC1=NON=C1C1=NC2=CC=CC=C2N1CC1=CC=C(Cl)C(Cl)=C1 VHBPIHGCMKHKLE-UHFFFAOYSA-N 0.000 claims 2
- NSIJURZMDSCFBL-UHFFFAOYSA-N 4-[1-[(3-bromophenyl)methyl]benzimidazol-2-yl]-1,2,5-oxadiazol-3-amine Chemical compound NC1=NON=C1C1=NC2=CC=CC=C2N1CC1=CC=CC(Br)=C1 NSIJURZMDSCFBL-UHFFFAOYSA-N 0.000 claims 2
- LAQLCMYZQGUKFA-UHFFFAOYSA-N 4-[1-[(4-chlorophenyl)methyl]benzimidazol-2-yl]-1,2,5-oxadiazol-3-amine Chemical compound NC1=NON=C1C1=NC2=CC=CC=C2N1CC1=CC=C(Cl)C=C1 LAQLCMYZQGUKFA-UHFFFAOYSA-N 0.000 claims 2
- ITWVPIOKFJWICI-UHFFFAOYSA-N 4-[1-[(4-methylphenyl)methyl]benzimidazol-2-yl]-1,2,5-oxadiazol-3-amine Chemical compound C1=CC(C)=CC=C1CN1C2=CC=CC=C2N=C1C1=NON=C1N ITWVPIOKFJWICI-UHFFFAOYSA-N 0.000 claims 2
- PQJCCZPMTJZYDF-UHFFFAOYSA-N 4-[2-(4-amino-1,2,5-oxadiazol-3-yl)benzimidazol-1-yl]butanenitrile Chemical compound NC1=NON=C1C1=NC2=CC=CC=C2N1CCCC#N PQJCCZPMTJZYDF-UHFFFAOYSA-N 0.000 claims 2
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 claims 2
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Natural products C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 claims 2
- 125000004423 acyloxy group Chemical group 0.000 claims 2
- 125000005605 benzo group Chemical group 0.000 claims 2
- QEPDSNAEMKSMGN-UHFFFAOYSA-N chembl1329127 Chemical compound NC1=NON=C1C1=NC2=CC=CC=C2N1 QEPDSNAEMKSMGN-UHFFFAOYSA-N 0.000 claims 2
- 125000003838 furazanyl group Chemical group 0.000 claims 2
- IKUGCHSAVSKMEA-UHFFFAOYSA-N n-[2-(1h-benzimidazol-2-yl)phenyl]acetamide Chemical compound CC(=O)NC1=CC=CC=C1C1=NC2=CC=CC=C2N1 IKUGCHSAVSKMEA-UHFFFAOYSA-N 0.000 claims 2
- VPCQBVROXHOCLQ-UHFFFAOYSA-N n-[2-(1h-benzimidazol-2-yl)phenyl]propanamide Chemical compound CCC(=O)NC1=CC=CC=C1C1=NC2=CC=CC=C2N1 VPCQBVROXHOCLQ-UHFFFAOYSA-N 0.000 claims 2
- LGXJGCZIHDEMDL-UHFFFAOYSA-N n-[4-(1-ethylbenzimidazol-2-yl)-1,2,5-oxadiazol-3-yl]-2,2,2-trifluoroacetamide Chemical compound N=1C2=CC=CC=C2N(CC)C=1C1=NON=C1NC(=O)C(F)(F)F LGXJGCZIHDEMDL-UHFFFAOYSA-N 0.000 claims 2
- XUYDLORMICPNES-UHFFFAOYSA-N n-[4-[1-(cyanomethyl)benzimidazol-2-yl]-1,2,5-oxadiazol-3-yl]acetamide Chemical compound CC(=O)NC1=NON=C1C1=NC2=CC=CC=C2N1CC#N XUYDLORMICPNES-UHFFFAOYSA-N 0.000 claims 2
- 125000003373 pyrazinyl group Chemical group 0.000 claims 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims 2
- 125000001544 thienyl group Chemical group 0.000 claims 2
- FAIVIYCNLYZSDO-UHFFFAOYSA-N 4-(1-benzylbenzimidazol-2-yl)-1,2,5-oxadiazol-3-amine Chemical compound NC1=NON=C1C1=NC2=CC=CC=C2N1CC1=CC=CC=C1 FAIVIYCNLYZSDO-UHFFFAOYSA-N 0.000 claims 1
- NYUVVVDGKCTKKF-UHFFFAOYSA-N 4-[1-(2-methylpropyl)benzimidazol-2-yl]-1,2,5-oxadiazol-3-amine Chemical compound N=1C2=CC=CC=C2N(CC(C)C)C=1C1=NON=C1N NYUVVVDGKCTKKF-UHFFFAOYSA-N 0.000 claims 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 1
- 102000002254 Glycogen Synthase Kinase 3 Human genes 0.000 claims 1
- 108010014905 Glycogen Synthase Kinase 3 Proteins 0.000 claims 1
- 102000036243 Lymphocyte Specific Protein Tyrosine Kinase p56(lck) Human genes 0.000 claims 1
- 108010002481 Lymphocyte Specific Protein Tyrosine Kinase p56(lck) Proteins 0.000 claims 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 1
- 239000012472 biological sample Substances 0.000 claims 1
- 229910052799 carbon Inorganic materials 0.000 claims 1
- 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- MEXYDCGTNFLIOA-UHFFFAOYSA-N ethyl 2-[2-(4-amino-1,2,5-oxadiazol-3-yl)benzimidazol-1-yl]acetate Chemical compound N=1C2=CC=CC=C2N(CC(=O)OCC)C=1C1=NON=C1N MEXYDCGTNFLIOA-UHFFFAOYSA-N 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 1
- 125000003037 imidazol-2-yl group Chemical group [H]N1C([*])=NC([H])=C1[H] 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 1
- OLGMRMJENRKJRP-UHFFFAOYSA-N n-[2-(1h-benzimidazol-2-yl)phenyl]-2-methylpropanamide Chemical compound CC(C)C(=O)NC1=CC=CC=C1C1=NC2=CC=CC=C2N1 OLGMRMJENRKJRP-UHFFFAOYSA-N 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 150000001721 carbon Chemical class 0.000 description 2
- 125000001475 halogen functional group Chemical group 0.000 description 2
- 125000006615 aromatic heterocyclic group Chemical group 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US35484302P | 2002-02-06 | 2002-02-06 | |
| PCT/US2003/003655 WO2003066629A2 (en) | 2002-02-06 | 2003-02-06 | Heteroaryl compounds useful as inhibitors of gsk-3 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010043557A Division JP2010132697A (ja) | 2002-02-06 | 2010-02-26 | Ｇｓｋ−３の阻害剤として有用なヘテロアリール化合物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2005526028A JP2005526028A (ja) | 2005-09-02 |
| JP2005526028A5 true JP2005526028A5 (enExample) | 2011-01-06 |
| JP4656838B2 JP4656838B2 (ja) | 2011-03-23 |
Family
ID=27734431
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003566002A Expired - Fee Related JP4656838B2 (ja) | 2002-02-06 | 2003-02-06 | Ｇｓｋ−３の阻害剤として有用なヘテロアリール化合物 |
| JP2010043557A Pending JP2010132697A (ja) | 2002-02-06 | 2010-02-26 | Ｇｓｋ−３の阻害剤として有用なヘテロアリール化合物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010043557A Pending JP2010132697A (ja) | 2002-02-06 | 2010-02-26 | Ｇｓｋ−３の阻害剤として有用なヘテロアリール化合物 |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US20040034037A1 (enExample) |
| EP (2) | EP1472245A2 (enExample) |
| JP (2) | JP4656838B2 (enExample) |
| KR (1) | KR20040084896A (enExample) |
| AU (1) | AU2003215087B2 (enExample) |
| CA (1) | CA2475633C (enExample) |
| ES (1) | ES2437391T3 (enExample) |
| MX (1) | MXPA04007697A (enExample) |
| NO (1) | NO20043726L (enExample) |
| PL (1) | PL372198A1 (enExample) |
| RU (1) | RU2004126671A (enExample) |
| SG (1) | SG159380A1 (enExample) |
| WO (1) | WO2003066629A2 (enExample) |
Families Citing this family (117)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002022605A1 (en) * | 2000-09-15 | 2002-03-21 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
| GB0206861D0 (en) * | 2002-03-22 | 2002-05-01 | Glaxo Group Ltd | Medicaments |
| GB0206860D0 (en) * | 2002-03-22 | 2002-05-01 | Glaxo Group Ltd | Compounds |
| US20040002524A1 (en) * | 2002-06-24 | 2004-01-01 | Richard Chesworth | Benzimidazole compounds and their use as estrogen agonists/antagonists |
| AU2003290346A1 (en) * | 2002-12-24 | 2004-07-22 | Biofocus Plc | Compound libraries of 2,3-substituted pyrazine derivatives capable of binding to g-protein coupled receptors |
| WO2004069160A2 (en) * | 2003-01-28 | 2004-08-19 | Smithkline Beecham Corporation | Chemical compounds |
| JP2006520794A (ja) | 2003-03-21 | 2006-09-14 | スミスクライン ビーチャム コーポレーション | 化合物 |
| CN100434428C (zh) * | 2003-05-23 | 2008-11-19 | 巴斯利尔药物股份公司 | 呋咱并苯并咪唑类化合物 |
| TWI372050B (en) | 2003-07-03 | 2012-09-11 | Astex Therapeutics Ltd | (morpholin-4-ylmethyl-1h-benzimidazol-2-yl)-1h-pyrazoles |
| AR045134A1 (es) * | 2003-07-29 | 2005-10-19 | Smithkline Beecham Plc | Compuesto de 1h - imidazo [4,5-c] piridin-ilo, composicion farmaceutica que lo comprende, proceso para prepararla, su uso para preparar dicha composicion farmaceutica, combinacion farmaceutica, uso de la combinacion farmaceutica para la preparacion de un medicamento, procedimientos para preparar dic |
| JP2007512230A (ja) | 2003-08-20 | 2007-05-17 | バーテックス ファーマシューティカルズ インコーポレイテッド | プロテインキナーゼ阻害剤として有用な（４−アミノ−１，２，５−オキサジアゾール−４−イル）−ヘテロ芳香族化合物 |
| EP1670466A4 (en) * | 2003-10-06 | 2007-04-25 | Glaxo Group Ltd | PREPARATION OF 1,6,7-TRISUBSTITUTED AZABENIC ZIMIDAZOLES AS KINASE-INHIBITORS |
| DE102004010194A1 (de) | 2004-03-02 | 2005-10-13 | Aventis Pharma Deutschland Gmbh | 4-Benzimidazol-2-yl-pyridazin-3-on-Derivate, ihre Herstellung und Verwendung in Arzneimitteln |
| DE102004010207A1 (de) | 2004-03-02 | 2005-09-15 | Aventis Pharma S.A. | Neue 4-Benzimidazol-2-yl-pyridazin-3-on-Derivate |
| US7772271B2 (en) | 2004-07-14 | 2010-08-10 | Ptc Therapeutics, Inc. | Methods for treating hepatitis C |
| US7868037B2 (en) | 2004-07-14 | 2011-01-11 | Ptc Therapeutics, Inc. | Methods for treating hepatitis C |
| US7781478B2 (en) | 2004-07-14 | 2010-08-24 | Ptc Therapeutics, Inc. | Methods for treating hepatitis C |
| JP2008506702A (ja) | 2004-07-14 | 2008-03-06 | ピーティーシー セラピューティクス，インコーポレーテッド | Ｃ型肝炎を治療するための方法 |
| NZ553329A (en) | 2004-07-22 | 2010-09-30 | Ptc Therapeutics Inc | Thienopyridines for treating hepatitis C |
| US7674907B2 (en) * | 2004-07-23 | 2010-03-09 | Amgen Inc. | Furanopyridine derivatives and methods of use |
| WO2006034207A2 (en) * | 2004-09-17 | 2006-03-30 | Vanderbilt University | Use of gsk3 inhibitors in combination with radiation therapies |
| GB0422057D0 (en) * | 2004-10-05 | 2004-11-03 | Astrazeneca Ab | Novel compounds |
| US20060204980A1 (en) * | 2004-12-28 | 2006-09-14 | Altieri Dario C | Colorectal cancer therapies |
| TWI427077B (zh) | 2004-12-30 | 2014-02-21 | Astex Therapeutics Ltd | 吡唑化合物及其用途和含有彼之藥學組成物 |
| US20080312223A1 (en) | 2004-12-30 | 2008-12-18 | Astex Therapeutics Limited | Thiazole And Isothiazole Derivatives That Modulate The Activity Of CDK, GSK And Aurora Kinases |
| CA2599989A1 (en) * | 2005-03-03 | 2006-09-08 | Sirtris Pharmaceuticals, Inc. | N-phenyl benzamide derivatives as sirtuin modulators |
| DK1871374T3 (da) * | 2005-04-21 | 2011-12-05 | Merck Serono Sa | 2,3-substituerede pyrazinsulfonamider som CRTH2-inhibitorer |
| AU2006251832A1 (en) * | 2005-05-27 | 2006-11-30 | Queen's University At Kingston | Treatment of protein folding disorders |
| DE102005025225A1 (de) * | 2005-06-01 | 2006-12-07 | Sanofi-Aventis Deutschland Gmbh | Verfahren zur Herstellung von 2-(2-Amino-pyrimidin-4-yl)-1H-indol-5-carbonsäure-derivaten |
| US7855289B2 (en) * | 2005-08-04 | 2010-12-21 | Sirtris Pharmaceuticals, Inc. | Sirtuin modulating compounds |
| EP2388263A1 (en) * | 2005-08-04 | 2011-11-23 | Sirtris Pharmaceuticals, Inc. | Imidazo[2,1-b]thiazole derivatives as sirtuin modulators |
| US8088928B2 (en) * | 2005-08-04 | 2012-01-03 | Sirtris Pharmaceuticals, Inc. | Sirtuin modulating compounds |
| US8093401B2 (en) | 2005-08-04 | 2012-01-10 | Sirtris Pharmaceuticals, Inc. | Sirtuin modulating compounds |
| AR057525A1 (es) * | 2005-10-03 | 2007-12-05 | Astrazeneca Ab | Compuestos inhibidores selectivos de gsk3 y un proceso para su preparacion |
| UY29825A1 (es) * | 2005-10-03 | 2007-05-31 | Astrazeneca Ab | Derivados sustituidos de 3h-imidazol-(4,5 b (beta))piridina-2-il benzoatos y benzamidas, composiciones farmacéuticas que los contienen y aplicaciones |
| US7625890B2 (en) | 2005-11-10 | 2009-12-01 | Smithkline Beecham Corp. | Substituted imidazo[4,5-c]pyridine compounds as Akt inhibitors |
| EP1968579A1 (en) | 2005-12-30 | 2008-09-17 | Astex Therapeutics Limited | Pharmaceutical compounds |
| AU2007351886A1 (en) * | 2006-06-23 | 2008-10-30 | Paratek Pharmaceuticals, Inc. | Transcription factor modulating compounds and methods of use thereof |
| JP5523829B2 (ja) | 2006-06-29 | 2014-06-18 | アステックス、セラピューティックス、リミテッド | 複合薬剤 |
| BRPI0713946A2 (pt) * | 2006-06-29 | 2012-12-04 | Hoffmann La Roche | compostos, composições farmacêuticas que os compreendem, método para o tratamento terapêutico e/ou profilático de enfermidades que são moduladas por agonistas de fxr, e uso dos compostos |
| WO2008052072A2 (en) * | 2006-10-24 | 2008-05-02 | Acadia Pharmaceuticals Inc. | Compounds for the treatment of pain and screening methods therefor |
| EP2081892A4 (en) * | 2006-11-17 | 2014-03-05 | Donald F Weaver | COMPOUNDS AND METHOD FOR THE TREATMENT OF PROTEIN DISAPPEARANCE |
| SG144809A1 (en) | 2007-01-11 | 2008-08-28 | Millipore U K Ltd | Benzimidazole compounds and their use as chromatographic ligands |
| UY30892A1 (es) * | 2007-02-07 | 2008-09-02 | Smithkline Beckman Corp | Inhibidores de la actividad akt |
| TW200916472A (en) * | 2007-06-20 | 2009-04-16 | Sirtris Pharmaceuticals Inc | Sirtuin modulating compounds |
| GB0713259D0 (en) * | 2007-07-09 | 2007-08-15 | Astrazeneca Ab | Pyrazine derivatives 954 |
| WO2009024825A1 (en) * | 2007-08-21 | 2009-02-26 | Astrazeneca Ab | 2-pyrazinylbenzimidazole derivatives as receptor tyrosine kinase inhibitors |
| EP2188263B1 (en) * | 2007-08-27 | 2012-06-27 | F. Hoffmann-La Roche AG | Benzimidazole derivatives used as fxr agonists |
| JP2011500778A (ja) | 2007-10-25 | 2011-01-06 | アストラゼネカ・アクチエボラーグ | ピリジン及びピラジン誘導体−０８３ |
| EP2215066A1 (en) * | 2007-11-01 | 2010-08-11 | Sirtris Pharmaceuticals, Inc. | Amide derivatives as sirtuin modulators |
| AU2008325148A1 (en) * | 2007-11-08 | 2009-05-14 | Sirtris Pharmaceuticals, Inc. | Solubilized thiazolopyridines |
| AU2008323017B2 (en) | 2007-11-15 | 2012-12-20 | F. Hoffmann-La Roche Ag | Methyl-benzimidazole derivatives |
| US7816540B2 (en) * | 2007-12-21 | 2010-10-19 | Hoffmann-La Roche Inc. | Carboxyl- or hydroxyl-substituted benzimidazole derivatives |
| RU2011107227A (ru) * | 2008-07-30 | 2012-09-10 | Онкотерапи Сайенс, Инк. (Jp) | Бензоимидазольные производные и ингибиторы гликоген-синтаза-киназы-3 бета, содержащие такие производные |
| KR101712576B1 (ko) | 2008-11-10 | 2017-03-06 | 버텍스 파마슈티칼스 인코포레이티드 | Ａｔｒ 키나제의 억제제로서 유용한 화합물 |
| CA2747715A1 (en) | 2008-12-19 | 2010-06-24 | Sirtris Pharmaceuticals, Inc. | Thiazolopyridine sirtuin modulating compounds |
| PL2376485T3 (pl) | 2008-12-19 | 2018-05-30 | Vertex Pharmaceuticals Incorporated | Pochodne pirazyny użyteczne jako inhibitory kinazy ATR |
| MX2011008073A (es) * | 2009-01-30 | 2011-11-18 | Glaxosmithkline Llc | Hidrocloruro de n-{(1-s)-2-amino -1-[(3-fluorofenil)metil]etil}-5- cloro-4-(4-cloro-1-metil-1h-pirazol-5-il)-2-tiofenocarboxamida cristalino. |
| EP2251010A1 (en) * | 2009-05-08 | 2010-11-17 | Sygnis Bioscience GmbH & Co. KG | Use of thiabendazole and derivatives thereof for the therapy of neurological conditions |
| WO2010132684A2 (en) * | 2009-05-13 | 2010-11-18 | University Of Virginia Patent Foundation | Inhibitors of inv(16) leukemia |
| DE102009033208A1 (de) * | 2009-07-15 | 2011-01-20 | Merck Patent Gmbh | Aminopyridinderivate |
| NZ597376A (en) * | 2009-07-27 | 2014-01-31 | Basilea Pharmaceutica Ag | Furazanobenzimidazoles as prodrugs to treat neoplastic or autoimmune diseases |
| WO2011022721A1 (en) * | 2009-08-21 | 2011-02-24 | Microbiotix, Inc | Inhibitors of botulinum neurotoxins |
| AU2010314891A1 (en) | 2009-11-06 | 2012-06-07 | Vanderbilt University | Aryl and heteroaryl sulfones as MGLUR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction |
| WO2011143423A2 (en) | 2010-05-12 | 2011-11-17 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
| CA2798763A1 (en) | 2010-05-12 | 2011-11-17 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
| EP2569287B1 (en) | 2010-05-12 | 2014-07-09 | Vertex Pharmaceuticals Inc. | Compounds useful as inhibitors of atr kinase |
| US8969356B2 (en) | 2010-05-12 | 2015-03-03 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
| WO2011143419A1 (en) | 2010-05-12 | 2011-11-17 | Vertex Pharmaceuticals Incorporated | Pyrazines useful as inhibitors of atr kinase |
| MX2012013082A (es) | 2010-05-12 | 2013-05-09 | Vertex Pharma | Derivados de 2-aminopiridina utiles como iinhibidores de cinasa atr. |
| MX2013000103A (es) | 2010-06-23 | 2013-06-13 | Vertex Pharma | Derivados de pirrolo-pirazina utiles como inhibidores de cinasa art. |
| KR20140027974A (ko) | 2011-04-05 | 2014-03-07 | 버텍스 파마슈티칼스 인코포레이티드 | Ｔｒａ 키나제의 억제제로서 유용한 아미노피라진 화합물 |
| JP2014517079A (ja) | 2011-06-22 | 2014-07-17 | バーテックス ファーマシューティカルズ インコーポレイテッド | Ａｔｒキナーゼ阻害剤として有用な化合物 |
| EP2723747A1 (en) | 2011-06-22 | 2014-04-30 | Vertex Pharmaceuticals Inc. | Compounds useful as inhibitors of atr kinase |
| JP2014520161A (ja) | 2011-06-22 | 2014-08-21 | バーテックス ファーマシューティカルズ インコーポレイテッド | Ａｔｒキナーゼ阻害剤として有用な化合物 |
| EP2554662A1 (en) | 2011-08-05 | 2013-02-06 | M Maria Pia Cosma | Methods of treatment of retinal degeneration diseases |
| US20140235667A1 (en) | 2011-09-22 | 2014-08-21 | Merck Sharp & Dohme Corp. | Imidazopyridyl compounds as aldosterone synthase inhibitors |
| WO2013043521A1 (en) | 2011-09-22 | 2013-03-28 | Merck Sharp & Dohme Corp. | Pyrazolopyridyl compounds as aldosterone synthase inhibitors |
| EP2757883B1 (en) | 2011-09-22 | 2021-01-13 | Merck Sharp & Dohme Corp. | Triazolopyridyl compounds as aldosterone synthase inhibitors |
| WO2013049719A1 (en) | 2011-09-30 | 2013-04-04 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
| MX392542B (es) | 2011-09-30 | 2025-03-24 | Vertex Pharma | Tratamiento del cancer de pancreas y del cancer de pulmon de celulas no pequeñas con inhibidores de atr. |
| HUE046429T2 (hu) | 2011-09-30 | 2020-03-30 | Vertex Pharma | ATR kináz inhibítoraként használható vegyületek elõállítására szolgáló eljárás |
| US8853217B2 (en) | 2011-09-30 | 2014-10-07 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
| JP2014528419A (ja) | 2011-09-30 | 2014-10-27 | バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ | Ａｔｒキナーゼ阻害剤として有用な化合物 |
| EP2776422A1 (en) | 2011-11-09 | 2014-09-17 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
| EP2776420A1 (en) | 2011-11-09 | 2014-09-17 | Vertex Pharmaceuticals Incorporated | Pyrazine compounds useful as inhibitors of atr kinase |
| WO2013071088A1 (en) | 2011-11-09 | 2013-05-16 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
| WO2013071085A1 (en) | 2011-11-09 | 2013-05-16 | Vertex Pharmaceuticals Incorporated | Pyrazine compounds useful as inhibitors of atr kinase |
| WO2013071094A1 (en) | 2011-11-09 | 2013-05-16 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
| CN108478577A (zh) | 2012-04-05 | 2018-09-04 | 沃泰克斯药物股份有限公司 | 可用作atr激酶抑制剂的化合物及其组合疗法 |
| IN2014KN02601A (enExample) | 2012-04-24 | 2015-05-08 | Vertex Pharma | |
| US8999632B2 (en) | 2012-10-04 | 2015-04-07 | Vertex Pharmaceuticals Incorporated | Method for measuring ATR inhibition mediated increases in DNA damage |
| WO2014055595A1 (en) | 2012-10-05 | 2014-04-10 | Merck Sharp & Dohme Corp. | Indoline compounds as aldosterone synthase inhibitiors related applications |
| WO2014062604A1 (en) | 2012-10-16 | 2014-04-24 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
| JP2015535227A (ja) * | 2012-10-26 | 2015-12-10 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | Ｓｙｋの３，４−二置換１ｈ−ピラゾール及び４，５−二置換チアゾール阻害剤 |
| SMT202000713T1 (it) | 2012-12-07 | 2021-03-15 | Vertex Pharma | Pirazolo [1,5-a] pirimidine utili come inibitori dell'atr chinasi per il trattamento di malattie del cancro |
| SMT201900107T1 (it) | 2013-03-12 | 2019-02-28 | Vertex Pharma | Inibitori della dna-pk |
| US9663519B2 (en) | 2013-03-15 | 2017-05-30 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
| PL3424920T3 (pl) | 2013-10-17 | 2020-11-16 | Vertex Pharmaceuticals Incorporated | Kokryształy (S)-N-metylo-8-(1-((2'-metylo-4’,6'-dideutero-[4,5'-bipirymidyn]-6-ylo)amino)propan-2-ylo)chinolino-4-karboksyamidu i ich deuterowane pochodne jako inhibitory DNA-PK |
| ES2768678T3 (es) | 2013-12-06 | 2020-06-23 | Vertex Pharma | Compuesto de 2-amino-6-fluoro-N-[5-fluoro-piridin-3-il]pirazolo[1,5-a]pirimidin-3-carboxamida útil como inhibidor de la ATR quinasa, su preparación, diferentes formas sólidas y derivados radiomarcados de las mismas |
| JO3517B1 (ar) * | 2014-01-17 | 2020-07-05 | Novartis Ag | ان-ازاسبيرو الكان حلقي كبديل مركبات اريل-ان مغايرة وتركيبات لتثبيط نشاط shp2 |
| SG10201902206QA (en) | 2014-06-05 | 2019-04-29 | Vertex Pharma | Radiolabelled derivatives of a 2-amino-6-fluoro-n-[5-fluoro-pyridin-3-yl]- pyrazolo[1,5-a]pyrimidin-3-carboxamide compound useful as atr kinase inhibitor, the preparation of said compound and different solid forms thereof |
| CN106715424B (zh) | 2014-06-05 | 2020-07-14 | 拜耳作物科学股份公司 | 作为农药的双环化合物 |
| AU2015277212B2 (en) | 2014-06-17 | 2020-07-02 | Vertex Pharmaceuticals Incorporated | Method for treating cancer using a combination of Chk1 and ATR inhibitors |
| CN107567443B (zh) | 2014-12-24 | 2023-04-28 | 株式会社Lg化学 | 作为gpr120激动剂的联芳基衍生物 |
| RU2768621C1 (ru) | 2015-09-30 | 2022-03-24 | Вертекс Фармасьютикалз Инкорпорейтед | Способ лечения рака с использованием комбинации повреждающих днк средств и ингибиторов atr |
| EP3231434A1 (en) | 2016-04-14 | 2017-10-18 | Fundacio Centre de Regulacio Genomica | Method of treatment of parkinsonism |
| PT3468972T (pt) | 2016-06-14 | 2020-08-21 | Novartis Ag | Compostos e composições para inibir a atividade da shp2 |
| MX394860B (es) | 2016-09-27 | 2025-03-24 | Vertex Pharma | Metodo para tratar cancer usando una combinacion de agentes que dañan adn e inhibidores de proteina cinasa dependiente de adn (adn-pk). |
| CN116947836A (zh) | 2017-04-26 | 2023-10-27 | 巴斯利尔药物国际股份公司 | 制备呋咱并苯并咪唑及其晶型的方法 |
| WO2018217766A1 (en) | 2017-05-22 | 2018-11-29 | Whitehead Institute For Biomedical Research | Kcc2 expression enhancing compounds and uses thereof |
| CN109265451B (zh) * | 2018-10-09 | 2022-07-15 | 中国药科大学 | 丁酰胆碱酯酶选择性抑制剂及其制备方法与用途 |
| EP3920885A1 (en) | 2019-02-08 | 2021-12-15 | Frequency Therapeutics, Inc. | Valproic acid compounds and wnt agonists for treating ear disorders |
| CN111454254B (zh) | 2020-04-26 | 2023-06-02 | 云白药征武科技(上海)有限公司 | 一种具有含氟取代基的苯并咪唑衍生物的制备及其应用 |
| CN111423429A (zh) * | 2020-05-19 | 2020-07-17 | 江西科技师范大学 | 苯并咪唑联呋咱类系列化合物及其合成方法 |
| CN112920178A (zh) * | 2021-01-29 | 2021-06-08 | 中国药科大学 | 具有苯并咪唑结构的化合物及其制备方法与用途 |
| WO2024153225A1 (en) * | 2023-01-20 | 2024-07-25 | Pyrotech (Beijing) Biotechnology Co., Ltd. | Novel alpk1 inhibitors |
Family Cites Families (63)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3133081A (en) * | 1964-05-12 | J-aminoindazole derivatives | ||
| US3935183A (en) * | 1970-01-26 | 1976-01-27 | Imperial Chemical Industries Limited | Indazole-azo phenyl compounds |
| BE754242A (fr) * | 1970-07-15 | 1971-02-01 | Geigy Ag J R | Diamino-s-triazines et dinitro-s-triazines |
| US3998951A (en) * | 1974-03-13 | 1976-12-21 | Fmc Corporation | Substituted 2-arylquinazolines as fungicides |
| DE2458965C3 (de) * | 1974-12-13 | 1979-10-11 | Bayer Ag, 5090 Leverkusen | 3-Amino-indazol-N-carbonsäure-Derivate, Verfahren zu ihrer Herstellung sowie sie enthaltende Arzneimittel |
| DOP1981004033A (es) * | 1980-12-23 | 1990-12-29 | Ciba Geigy Ag | Procedimiento para proteger plantas de cultivo de la accion fitotoxica de herbicidas. |
| SE8102194L (sv) * | 1981-04-06 | 1982-10-07 | Pharmacia Ab | Terapeutiskt aktiv organisk forening och farmaceutisk beredning innehallande denna |
| SE8102193L (sv) * | 1981-04-06 | 1982-10-07 | Pharmacia Ab | Terapeutiskt aktiv organisk forening och dess anvendning |
| JPS58124773A (ja) * | 1982-01-20 | 1983-07-25 | Mitsui Toatsu Chem Inc | ５−メチルチオピリミジン誘導体とその製造法と農園芸用殺菌剤 |
| US5166170A (en) * | 1989-07-03 | 1992-11-24 | Hoechst-Roussel Pharmaceuticals Incorporated | 2-(aminoaryl) indoles and indolines as topical antiinflammatory agents for the treatment of skin disorders |
| US5710158A (en) * | 1991-05-10 | 1998-01-20 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase |
| US5496826A (en) * | 1994-09-02 | 1996-03-05 | Bristol-Myers Squibb Company | Pharmaceutical methods of using heterocyclic derivatives of N-phenylamides |
| EP0788358B1 (en) * | 1994-11-10 | 2004-03-31 | Millennium Pharmaceuticals, Inc. | Use of pyrazole compounds for the treatment of glomerulonephritis, cancer, atherosclerosis or restenosis |
| IL117659A (en) * | 1995-04-13 | 2000-12-06 | Dainippon Pharmaceutical Co | Substituted 2-phenyl pyrimidino amino acetamide derivative process for preparing the same and a pharmaceutical composition containing same |
| WO1997012613A1 (en) * | 1995-10-05 | 1997-04-10 | Warner-Lambert Company | Method for treating and preventing inflammation and atherosclerosis |
| US6716575B2 (en) * | 1995-12-18 | 2004-04-06 | Sugen, Inc. | Diagnosis and treatment of AUR1 and/or AUR2 related disorders |
| GB9619284D0 (en) * | 1996-09-16 | 1996-10-30 | Celltech Therapeutics Ltd | Chemical compounds |
| US6267952B1 (en) * | 1998-01-09 | 2001-07-31 | Geltex Pharmaceuticals, Inc. | Lipase inhibiting polymers |
| ATE245641T1 (de) * | 1998-02-17 | 2003-08-15 | Tularik Inc | Antivirale pyrimidinderivate |
| KR100581199B1 (ko) | 1998-06-19 | 2006-05-17 | 카이론 코포레이션 | 글리코겐 신타제 키나제 3의 억제제 |
| WO2000011003A1 (en) * | 1998-08-21 | 2000-03-02 | Du Pont Pharmaceuticals Company | ISOXAZOLO[4,5-d]PYRIMIDINES AS CRF ANTAGONISTS |
| US6184226B1 (en) * | 1998-08-28 | 2001-02-06 | Scios Inc. | Quinazoline derivatives as inhibitors of P-38 α |
| US6130333A (en) * | 1998-11-27 | 2000-10-10 | Monsanto Company | Bicyclic imidazolyl derivatives as phosphodiesterase inhibitors, pharmaceutical compositions and method of use |
| GB9828640D0 (en) | 1998-12-23 | 1999-02-17 | Smithkline Beecham Plc | Novel method and compounds |
| GB9828511D0 (en) * | 1998-12-24 | 1999-02-17 | Zeneca Ltd | Chemical compounds |
| DE19920936A1 (de) * | 1999-05-07 | 2000-11-09 | Basf Ag | Heterozyklisch substituierte Benzimidazole, deren Herstellung und Anwendung |
| GB9914258D0 (en) * | 1999-06-18 | 1999-08-18 | Celltech Therapeutics Ltd | Chemical compounds |
| ES2246240T3 (es) * | 1999-06-23 | 2006-02-16 | Sanofi-Aventis Deutschland Gmbh | Bencimidazoles sustituidos. |
| US20020065270A1 (en) * | 1999-12-28 | 2002-05-30 | Moriarty Kevin Joseph | N-heterocyclic inhibitors of TNF-alpha expression |
| AU782775B2 (en) * | 2000-02-05 | 2005-08-25 | Vertex Pharmaceuticals Incorporated | Pyrazole compositions useful as inhibitors of ERK |
| CA2400447C (en) * | 2000-02-17 | 2008-04-22 | Amgen Inc. | Kinase inhibitors |
| GB0004887D0 (en) * | 2000-03-01 | 2000-04-19 | Astrazeneca Uk Ltd | Chemical compounds |
| EP1136099A1 (en) * | 2000-03-23 | 2001-09-26 | Sanofi-Synthelabo | 2-(Indolylalkylamino)pyrimidone derivatives as GSK3beta inhibitors |
| EE200200715A (et) * | 2000-06-28 | 2004-08-16 | Astrazeneca Ab | Asendatud kinasoliini derivaadid ja nende kasutamine inhibiitoritena |
| US6613776B2 (en) * | 2000-09-15 | 2003-09-02 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
| US6660731B2 (en) * | 2000-09-15 | 2003-12-09 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
| US7473691B2 (en) * | 2000-09-15 | 2009-01-06 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
| US6610677B2 (en) * | 2000-09-15 | 2003-08-26 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
| WO2002022605A1 (en) * | 2000-09-15 | 2002-03-21 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
| JP4052573B2 (ja) * | 2000-09-15 | 2008-02-27 | バーテックス ファーマシューティカルズ インコーポレイテッド | イソオキサゾールおよびｅｒｋのインヒビターとしてのその使用 |
| DE10061863A1 (de) * | 2000-12-12 | 2002-06-13 | Basf Ag | Verfahren zur Herstellung von Triethylendiamin (TEDA) |
| US6716851B2 (en) * | 2000-12-12 | 2004-04-06 | Cytovia, Inc. | Substituted 2-aryl-4-arylaminopyrimidines and analogs as activators or caspases and inducers of apoptosis and the use thereof |
| WO2002050073A1 (en) * | 2000-12-19 | 2002-06-27 | Smithkline Beecham P.L.C. | Pyrazolo[3,4-c]pyridines as gsk-3 inhibitors |
| AP2003002825A0 (en) * | 2000-12-21 | 2003-09-30 | Vertex Pharma | Pyrazole compounds useful as protein kinase inhibitors |
| MY130778A (en) * | 2001-02-09 | 2007-07-31 | Vertex Pharma | Heterocyclic inhibitiors of erk2 and uses thereof |
| ES2292753T4 (es) * | 2001-03-29 | 2009-02-16 | Vertex Pharmaceuticals Incorporated | Inhibidores de quinasas n-terminales c-jun (jnk) y otras proteina quinasas. |
| AU2002338642A1 (en) * | 2001-04-13 | 2002-10-28 | Vertex Pharmaceuticals Incorporated | Inhibitors of c-jun n-terminal kinases (jnk) and other protein kinases |
| EP1383771A1 (en) * | 2001-04-20 | 2004-01-28 | Vertex Pharmaceuticals Incorporated | 9-deazaguanine derivatives as inhibitors of gsk-3 |
| EP2295550A3 (en) * | 2001-04-30 | 2011-12-14 | Vertex Pharmaceuticals Incorporated | Crystal structures of GSK-3beta protein and protein complexes and their use |
| CA2446864C (en) * | 2001-05-16 | 2011-02-15 | Vertex Pharmaceuticals Incorporated | Inhibitors of src and other protein kinases |
| EP1399440B1 (en) * | 2001-06-15 | 2009-06-03 | Vertex Pharmaceuticals Incorporated | 5-(2-aminopyrimidin-4-yl)benzisoxazoles as protein kinase inhibitors |
| ATE337312T1 (de) * | 2001-07-03 | 2006-09-15 | Vertex Pharma | Isoxazolyl-pyrimidines als inhibitoren von src- und lck-protein-kinasen |
| BR0213562A (pt) * | 2001-10-26 | 2004-08-31 | Aventis Pharma Inc | Benzimidazóis e análogos e seu uso como inibidores de cinases de proteìna |
| AU2002364536B2 (en) * | 2001-12-07 | 2008-10-23 | Vertex Pharmaceuticals, Inc. | Pyrimidine-based compounds useful as GSK-3 inhibitors |
| US7179826B2 (en) * | 2002-03-15 | 2007-02-20 | Vertex Pharmaceuticals Incorporated | Compositions useful as inhibitors of protein kinases |
| US7091343B2 (en) * | 2002-03-15 | 2006-08-15 | Vertex Pharmaceuticals Incorporated | Compositions useful as inhibitors of protein kinases |
| AU2003220300A1 (en) * | 2002-03-15 | 2003-09-29 | Binch, Hayley | Compositions useful as inhibitors of protein kinases |
| US20040009981A1 (en) * | 2002-03-15 | 2004-01-15 | David Bebbington | Compositions useful as inhibitors of protein kinases |
| US20030207873A1 (en) * | 2002-04-10 | 2003-11-06 | Edmund Harrington | Inhibitors of Src and other protein kinases |
| EP1506189A1 (en) * | 2002-04-26 | 2005-02-16 | Vertex Pharmaceuticals Incorporated | Pyrrole derivatives as inhibitors of erk2 and uses thereof |
| MY141867A (en) * | 2002-06-20 | 2010-07-16 | Vertex Pharma | Substituted pyrimidines useful as protein kinase inhibitors |
| JP4570955B2 (ja) * | 2002-07-09 | 2010-10-27 | バーテクス ファーマスーティカルズ インコーポレイテッド | プロテインキナーゼ阻害活性を持つイミダゾール類 |
| CN100434428C (zh) * | 2003-05-23 | 2008-11-19 | 巴斯利尔药物股份公司 | 呋咱并苯并咪唑类化合物 |
-
2003
- 2003-02-06 WO PCT/US2003/003655 patent/WO2003066629A2/en not_active Ceased
- 2003-02-06 AU AU2003215087A patent/AU2003215087B2/en not_active Ceased
- 2003-02-06 CA CA2475633A patent/CA2475633C/en not_active Expired - Fee Related
- 2003-02-06 PL PL03372198A patent/PL372198A1/xx not_active Application Discontinuation
- 2003-02-06 EP EP03710903A patent/EP1472245A2/en not_active Withdrawn
- 2003-02-06 KR KR10-2004-7012258A patent/KR20040084896A/ko not_active Withdrawn
- 2003-02-06 JP JP2003566002A patent/JP4656838B2/ja not_active Expired - Fee Related
- 2003-02-06 MX MXPA04007697A patent/MXPA04007697A/es not_active Application Discontinuation
- 2003-02-06 EP EP10180554.7A patent/EP2322521B1/en not_active Expired - Lifetime
- 2003-02-06 RU RU2004126671/04A patent/RU2004126671A/ru not_active Application Discontinuation
- 2003-02-06 US US10/360,535 patent/US20040034037A1/en not_active Abandoned
- 2003-02-06 SG SG200605228-6A patent/SG159380A1/en unknown
- 2003-02-06 ES ES10180554.7T patent/ES2437391T3/es not_active Expired - Lifetime
-
2004
- 2004-09-06 NO NO20043726A patent/NO20043726L/no unknown
-
2007
- 2007-07-12 US US11/776,756 patent/US20070270420A1/en not_active Abandoned
-
2010
- 2010-02-26 JP JP2010043557A patent/JP2010132697A/ja active Pending